FDA Approves Stimufend (pegfilgrastim-fpgk), a Biosimilar to Neulasta
September 6, 2022 -- Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 6, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- May 27, 2022 -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the“Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 27, 2022 Category: Drugs & Pharmacology Source Type: news

Releuko (Filgrastim-ayow Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2022 Category: Drugs & Pharmacology Source Type: news

Oncology Care Model Reduces Cost of Supportive Care Meds Oncology Care Model Reduces Cost of Supportive Care Meds
The Oncology Care Model led to notable reductions in the use of the pricy monoclonal antibody denosumab, more rapid adoption of the biosimilar filgrastim, and more selective use of costly antiemetics.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
February 28, 2022 -- The United States (U.S.) Food and Drug Administration (FDA) has approved Releuko (filgrastim-ayow), a biosimilar to Neupogen (filgrastim). The FDA approval was based on a review of data that demonstrated a high degree of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2022 Category: Drugs & Pharmacology Source Type: news

Drug maker Lupin inks licensing pact with Axantia for Pegfilgrastim
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Lupin had earlier received the USFDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 1, 2022 Category: Pharmaceuticals Source Type: news

Drug maker Lupin inks licensing pact with Axantia for Pegfilgrastim
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Lupin had earlier received the USFDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim). (Source: The Economic Times)
Source: The Economic Times - February 1, 2022 Category: Consumer Health News Source Type: news

FDA notifies Amgen of misbranding of its biological product, Neulasta, due to false or misleading promotional communications about the product ’s benefit
The Food and Drug Administration (FDA) has issued an untitled letter to Amgen Inc. for the misbranding of its biological product, Neulasta (pegfilgrastim) injection, for subcutaneous use, resulting from a false or misleading promotional communication. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 14, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2021 Category: Biotechnology Authors: Laura Newpoff Source Type: news

Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 29, 2021 Category: American Health Authors: Laura Newpoff Source Type: news

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Neulasta (pegfilgrastim)
Title: Neulasta (pegfilgrastim)Category: MedicationsCreated: 3/19/2021 12:00:00 AMLast Editorial Review: 3/19/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 19, 2021 Category: Cancer & Oncology Source Type: news

Nivestym (Filgrastim-aafi Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 20, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta
NEW YORK--(BUSINESS WIRE)-- June 11, 2020 -- Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 Nyvepria is... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 11, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
Holzkirchen, Nov. 5, 2019– Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar Ziextenzo (pegfilgrastim-bmez). Sandoz biosimilar pegfilgrastim... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 5, 2019 Category: Drugs & Pharmacology Source Type: news